摘要
Breast cancer is the most common malignant tumour in women,and it has a high incidence and mortality rate both in the world and in China.Hormone receptor-positive breast cancer accounts for about 60–70%of breast cancer and is the most common subtype of advanced breast cancer.Cyclin-dependent kinase 4 and 6(CDK 4/6)inhibitors in combination with endocrine therapy have emerged as the treatment of choice for hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer.Emergence inhibitors of CDK 4/6 have significantly improved outcomes in patients with hormone receptor-positive advanced breast cancer.It is an indisputable fact that cardiotoxicity caused by breast cancer treatment can have a significant impact on the quality of life of cancer survivors;however,there are few studies on the cardiovascular toxicity of CDK 4/6 inhibitors.This article reviews the cardiovascular toxicity and related mechanisms that may be caused by CDK 4/6 inhibitors.
